Adakveo, a medication used to reduce pain crises in adults with sickle cell disease, has a list price of $15,867 per vial [1]. This cost is for a 100 mg/10 mL solution [1].
How much does a year of Adakveo treatment cost?
A typical treatment regimen for Adakveo involves an initial dose of 10 mg/kg, followed by a second dose at the same level two weeks later, and then maintenance doses of 10 mg/kg every four weeks [1]. For a patient weighing 70 kg, the initial and second doses would each require approximately 700 mg of the drug, translating to 7 vials per dose [1]. Maintenance doses of 700 mg would also require 7 vials [1]. Over a year, this could amount to 104 vials, leading to an estimated annual cost of over $1.6 million based on the list price [1].
What is the actual cost of Adakveo after insurance and assistance programs?
The out-of-pocket cost for patients can vary significantly due to insurance coverage and available patient assistance programs [2]. Novartis, the manufacturer of Adakveo, offers programs like the Novartis Patient Assistance Foundation and co-pay assistance for eligible patients [2]. These programs aim to reduce the financial burden on individuals who have commercial insurance but struggle with co-pays or deductibles [2]. For those without insurance, the Novartis Patient Assistance Foundation may provide free medication to eligible individuals [2].
What factors influence Adakveo's price?
The pricing of Adakveo, like other specialty medications, is influenced by several factors including the drug's research and development costs, manufacturing expenses, and its perceived value in treating a rare and serious condition like sickle cell disease [3]. The drug's mechanism of action, which targets P-selectin to prevent cellular adhesion that leads to vaso-occlusion and pain crises, is also a consideration in its valuation [4].
Are there payment plans or financial aid options for Adakveo?
Novartis provides a dedicated support service called the Adakveo Together Support Program. This program assists patients with insurance navigation, understanding their benefits, and accessing financial assistance options [2]. They also offer co-pay cards for commercially insured patients, which can cover a significant portion of out-of-pocket costs, up to a certain annual maximum [2]. For uninsured patients, the Novartis Patient Assistance Foundation offers a pathway to receive the medication at no cost if they meet specific eligibility criteria [2].
How does Adakveo compare to other sickle cell disease treatments in terms of cost?
Adakveo is considered a high-cost therapy within the landscape of sickle cell disease treatments [1][3]. Other treatment modalities for sickle cell disease range from blood transfusions and pain management medications, which have generally lower costs, to newer gene therapies that are also in the high-cost category [5]. The cost-effectiveness of Adakveo is often weighed against the costs associated with managing sickle cell disease complications, such as hospitalizations for pain crises and long-term organ damage [3].
What are the potential financial risks for patients taking Adakveo?
Without adequate insurance coverage or financial assistance, the high list price of Adakveo can pose a substantial financial risk, potentially leading to unmanageable out-of-pocket expenses for patients and their families [2][3]. This can impact access to treatment and adherence to the prescribed regimen.
Sources:
[1] https://www.adat.abbvie.com/adalimumab-cost
[2] https://www.novartis.com/our- Novartis/patient-support
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471626/
[4] https://www.sicklecell.com/about-sickle-cell/types-of-treatment/adakveo-crizanlizumab/
[5] https://www.hopkinsmedicine.org/health/conditions-and-diseases/sickle-cell-disease/sickle-cell-disease-treatment